APILIMOD COMPOSITIONS AND METHODS FOR USING SAME IN THE TREATMENT OF ALZHEIMER'S DISEASE
The present disclosure relates to methods for treating Alzheimer's disease with apilimod and related compositions and methods.
1 . A method for treating dementia in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising apilimod in an amount effective to inhibit the processing of amyloid precursor protein (APP) into abeta (Ab) peptides in a cell of the subject.
2 . The method of claim 1 , wherein the cell is a neural cell.
3 . The method of claim 1 , wherein the pharmaceutical composition is an oral dosage form.
4 . The method of claim 1 , further comprising administering to the subject at least one additional agent.
5 . The method of claim 4 , wherein the at least one additional agent is a therapeutic agent.
6 . The method of claim 5 , wherein the therapeutic agent is a cholinesterase inhibitor.
7 . The method of claim 4 , wherein the at least one additional agent is administered in the same dosage form as the apilimod.
8 . The method of claim 4 , wherein the at least one additional agent is administered in a different dosage form from the apilimod.
9 . The method of claim 7 , wherein the dosage form is an oral dosage form.
10 . The method of claim 1 , wherein the dementia is Alzheimer's disease.
11 . The method of claim 10 , wherein the method is effective to alleviate at least one symptom of Alzheimer's disease in the patient, or effective to slow the progression of Alzheimer's disease in the patient.
12 . The method of claim 1 , wherein the apilimod is 2-[2-Pyridin-2-yl)-ethoxy]-4-N′-(3-methyl-benzilidene)-hydrazino]-6-(morpholin-4-yl)-pyrimidine (IUPAC name: (E)-4-(6-(2-(3-methylbenzylidene)hydrazinyl)-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine).
13 . A method for inhibiting the processing of amyloid precursor protein (APP) into abeta (Ab) peptides in a cell, the method comprising contacting the cell with an amount of apilimod effective to inhibit APP processing into Ab peptides.
14 . The method of claim 13 , wherein the cell is in vitro or in vivo.
15 . The method of claim 14 , wherein the cell is part of a tissue.
16 . The method of claim 15 , wherein the tissue is neural tissue.
17 . The method of claim 13 , wherein the apilimod is 2-[2-Pyridin-2-yl)-ethoxy]-4-N′-(3-methyl-benzilidene)-hydrazino]-6-(morpholin-4-yl)-pyrimidine (IUPAC name: (E)-4-(6-(2-(3-methylbenzylidene)hydrazinyl)-2-(2-(pyridin-2-yl)ethoxy)pyrimidin-4-yl)morpholine).